Humanized Mice Recapitulate Key Features of HIV-1 Infection: A Novel Concept Using Long-Acting Anti-Retroviral Drugs for Treating HIV-1
Figure 4
Two long-acting drugs, TMC278-LA (160 mg/kg) and TMC181-LA (400 mg/kg), are highly effective as maintenance therapy.
(A) Response to a quadruple ART consisting of 3TC, TDF, TMC278-LA and TMC181-LA over a treatment period of 150 days (the black circles identifies the mice which remained over the entire time on ART (n = 7), the white circles identify the mice which were subsequently switched to a treatment with double long-acting drugs (see (B)). (B) Sustained successful suppression of HIV RNA after switching mice with suppressed HIV RNA under quadruple ART to a treatment with double long-acting drugs (n = 8). (C) Mock-treated HIV infected mice (n = 5). (D) CD4+ T-cells as determined by the CD4/CD8 cell ratio in all treated mice (ART and double long-acting drugs) and mock-treated mice at the end of the experiment.